Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience

Abstract

<p> <span style="font-size:10.0pt;"><span style="font-family:Verdana;">Objectives: We sought to evaluate the efficacy and safety of unrestricted implantation of everolimus eluting stent Xience V (EES-XV) in a cohort of real- world patients with unprotected left main coronary disease (ULMCD). Background: The second-generation EES-XV stent is currently one of the most commonly used drug-eluting stents in clinical practice. It has been shown to be superior to paclitaxel-eluting stents, but its relative merits on unprotected left main coronary disease have been less extensively assessed. </span><span style="font-family:Verdana;">Methods: Between 2007 and 2010, in this sin</span><span style="font-family:Verdana;">gle-center registry, we evaluated the clinical outcomes of 98 patients with ULMCD who underwent percutaneous coronary intervention (PCI) with EES-XV. Results: There were no in-hospital deaths. At 25.63 </span></span><span style="font-size:10pt;font-family:Verdana;">±</span><span style="font-size:10pt;font-family:Verdana;"> 14.41 months of follow-up, 17 patients (17.3%) experienced major adverse coronary event (MACE), death from cardiovascular disease (n = 6; 6.1%) and target lesion revascularization (TLR; n = 7; 7.1%). The predictors of death from cardiovascular disease were: previous PCI and left ventricular dysfunction. The only predictor of TLR was the placement of 2 stents in the left main coronary artery. Conclusions: In this single- center real-world registry, we found that elective ULMCD stenting with EES-XV provided good short-, medium- and long-term outcomes, with an estimated cumulative need for TLR of 7.1%, a cardiac mortality rate of 6.1%, and a MACE rate of 17.3% at 2 years.</span> </p